Indivior Pharmaceuticals Free Cash Flow (FCF) History (INDV)

Indivior Pharmaceuticals reported −$93.0M in free cash flow for fiscal 2025, a decrease of $100.0M from the previous fiscal year, with a free cash flow margin of −7.51%.

View full Indivior Pharmaceuticals company overview

Indivior Pharmaceuticals free cash flow by year

Indivior Pharmaceuticals annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20252025-12-31−$93.0M−$100.0M−7.51%
20242024-12-31$7.0M$315.0M+0.59%
20232023-12-31−$308.0M−$299.0M−28.18%
20222022-12-31−$9.0M−$358.0M−1.00%
20212021-12-31$349.0M+44.12%

Indivior Pharmaceuticals free cash flow growth trends

Indivior Pharmaceuticals's latest reported quarter, Q2 2026, generated $222.0M in free cash flow, an increase of 57.45% year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Indivior Pharmaceuticals filings at SEC.gov ↗